Retrospective Cohort Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Aug 21, 2020; 26(31): 4624-4638
Published online Aug 21, 2020. doi: 10.3748/wjg.v26.i31.4624
Table 6 Kaplan-Meier survival estimates
VariableNo. of casesDFS P valueOS P value
Sex (n, %)0.6680.448
Male160 (69.3)
Female71 (30.7)
Age (year)0.5180.688
< 60111 (48.1)
≥ 60120 (51.9)
ASA (n, %)0.6910.658
17 (3)
2178 (77)
346 (19.9)
BMI (kg/m2)0.7590.587
< 25149 (64.5)
≥ 2582 (35.5)
Interval time, w (%)0.0020.259
≤ 9 wk139 (60.2)
> 9 wk92 (39.8)
cT, n (%)0.3430.483
22 (0.9)
3180 (77.9)
449 (21.2)
cN, n (%)0.0590.084
062 (26.8)
1119 (51.5)
250 (21.6)
ypT, n (%)< 0.0010.001
040 (17.3)
15 (2.2)
248 (20.8)
3121 (52.4)
417 (7.4)
ypN, n (%)0.0010.185
0128 (55.4)
174 (32)
229 (12.6)
Surgical procedure0.1090.464
Miles (n, %)100 (43.3)
Dixon (n, %)113 (48.9)
Hartmann (n, %)18 (7.8)
Postoperative complications, n (%)0.2650.043
Yes12 (5.2)
No219 (94.8)
Degree of differentiation, n (%)0.0940.183
Low and low-moderate grades32 (13.9)
Moderate, moderate-high, and high grades193 (83.5)
Signet-ring and mucinous adenocarcinoma6 (2.6)
Preoperative concurrent chemotherapy regimen, n (%)0.3570.533
Capecitabine + oxaliplatin71 (30.7)
Capecitabine oral145 (62.8)
Oxaliplatin union15 (6.5)